Patents Represented by Attorney, Agent or Law Firm Naomi S. Biswas
-
Patent number: 6818404Abstract: The invention provides amplification-based methods for detecting hypermethylated nucleic acid in heterogeneous biological samples, e.g., stool. A screening procedure based on the detection of hypermethylation, preferably at multiple genes, provides a means for detecting various diseases, e.g., colorectal cancer. By using chimeric primers that contain a 5′ non-specific portion, the specificity and efficiency of the nucleic acid amplification is improved. Methods of the invention are especially useful in detection of rare events in a heterogeneous sample.Type: GrantFiled: April 11, 2002Date of Patent: November 16, 2004Assignee: Exact Sciences CorporationInventor: Anthony P. Shuber
-
Patent number: 6818741Abstract: The subject invention addresses the need for methods of treatment and prevention of breast cancer, and other cancers, by providing a peptide of eight to twenty amino acids in length which comprises a hydrophilic analog of an alpha-fetoprotein peptide having SEQ ID NO: 6: EMTPVNPG. The peptides may be linear, but are preferably cyclic. The peptides may be provided as dimers or other multimers. A composition comprising the peptide, an antibody that specifically binds to the peptide, a method of reducing estrogen-stimulated growth of cells using the peptide, as well as a method of treating or preventing cancer, such as breast cancer, are also provided. The treatment or prevention method can include the use of tamoxifen therapy in combination with the peptide therapy.Type: GrantFiled: June 2, 2001Date of Patent: November 16, 2004Assignee: CLF Medical Technology Acceleration Program, Inc.Inventors: Thomas T. Andersen, James A. Bennett, Herbert I. Jacobson, Fassil B. Mesfin
-
Patent number: 6777388Abstract: The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.Type: GrantFiled: August 19, 1999Date of Patent: August 17, 2004Assignee: CLF Medical Technology Acceleration Program, Inc.Inventors: Patricia Grasso, Daniel W. Lee, Matthew C. Leinung
-
Patent number: 6773702Abstract: A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.Type: GrantFiled: December 26, 2001Date of Patent: August 10, 2004Assignees: OXiGENE, Inc., Bristol-Myers Squibb CompanyInventors: Ronald W. Pero, Francis Y. F. Lee, Klaus Edvardsen, Hans Olov Sjögren
-
Patent number: 6757923Abstract: An easy-change mattress safety sheet system has a top panel that is completely removable and a bottom base that covers the underneath and four sides of a mattress. The base is designed to secure the top panel in place. The top and bottom panels are secured by a simple attaching means that covers the entire perimeter of the top plane of the mattress. The top panel can be completely removed from the base of the sheet by unfastening the simple attaching means. Removal of the top panel can be easily accomplished without disturbing the mattress, sheet base or crib bumpers. The sheet is secure on the mattress and will not allow entanglement of the child in the fabric.Type: GrantFiled: May 1, 2002Date of Patent: July 6, 2004Assignee: Clouds and Stars, Inc.Inventors: Elizabeth Sopher, Joan Henehan
-
Patent number: 6699967Abstract: The present invention provides HDGFX, a novel isolated polypeptide, as well as a polynucleotide encoding HDGFX and antibodies that immunospecifically bind to HDGFX or any derivative, variant, mutant, or fragment of the HDGFX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the HDGFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: September 28, 2000Date of Patent: March 2, 2004Assignee: CuraGen CorporationInventors: Catherine Burgess, Richard A. Shimkets, Corine Vernet, Ferenc L. Boldog, Meiji Yang, William J. La Rochell, Stacey Minskoff
-
Patent number: 6689866Abstract: The present invention provides novel isolated SECX polynucleotides and the membrane-associated or secreted polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: March 8, 2000Date of Patent: February 10, 2004Assignee: CuraGen CorporationInventor: Richard A. Shimkets
-
Patent number: 6670344Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.Type: GrantFiled: September 11, 2001Date of Patent: December 30, 2003Assignee: Bristol-Myers Squibb CompanyInventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
-
Patent number: 6627405Abstract: The present invention relates to complexes of the 53BP2 protein with proteins identified as interacting with 53BP2 by a yeast two hybrid assay system. The proteins identified to interact with 53BP2 are &bgr;-tubulin, p62, hnRNP G, and three gene products, 53BP2-IP1, 53BP2-IP2, and 53BP2-IP3 encoded, in part, by the EST R72810 sequence. Thus, the invention provides complexes of 53BP2 and &bgr;-tubulin, p62, hnRNP G, 53BP2-IP1, 53BP2-IP2, and 53BP2-IP3 and derivatives, fragments and analogs thereof. The invention also provides the 53BP2-IP1, 53BP2-IP2 and 53BP2-IP3 genes and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, autoimmune disease and neurodegenerative disease are also provided.Type: GrantFiled: June 22, 1999Date of Patent: September 30, 2003Assignee: CuraGen CorporationInventors: Krishnan Nandabalan, Meijia Yang, Vincent Peter Schulz
-
Patent number: 6620615Abstract: Disclosed is a nucleic acid encoding a novel G-protein coupled receptor and methods of using the same. The novel-G-protein coupled receptor was identified as a member of a set of genes that are differentially expressed in diseased fibroblasts relative to non-diseased fibroblasts. The invention also provides methods for identifying and treating disease based on the set of differentially expressed sequences.Type: GrantFiled: April 20, 2000Date of Patent: September 16, 2003Assignee: CuraGen CorporationInventor: Bonnie Gould-Rothberg
-
Patent number: 6600019Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: January 4, 2001Date of Patent: July 29, 2003Assignee: CuraGen CorporationInventors: Sudhirdas K. Prayaga, Kumud Majumder, Bruce Taillon, Steven Kurt Spaderna, Kimberly Spytek, John MacDougall
-
Patent number: 6537554Abstract: Novel angiogenesis/anti-angiogenesis secreted proteins and the nucleic acid sequences which encode them are disclosed by the present invention.Type: GrantFiled: September 11, 2000Date of Patent: March 25, 2003Assignee: Curagen CorporationInventors: Richard A. Shimkets, Michael Jeffers
-
Patent number: 6514939Abstract: The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.Type: GrantFiled: October 28, 1999Date of Patent: February 4, 2003Assignee: CuraGen CorporationInventor: Richard August Shimkets
-
Patent number: 6476193Abstract: The present invention discloses complexes of the Nlk1 protein with proteins identified as interacting with the Nlk1 protein (Nlk1 protein-IPs) by a modified, improved yeast two hybrid assay system. The proteins which were identified to interact with the Nlk1 protein, and thus form complexes, included: TrkA, protein phosphatase 1&agr;, 14-3-3&egr;, &agr;-tropomyosin, vimentin, p0071, Ini-1, IP-1, IP-2, IP-3, IP-4 and IP-5, as well as derivatives, fragments analogs and homologs thereof. Methodologies of screening these aforementioned complexes for efficacy in treating and/or preventing various diseases and disorders, particularly, neoplasia, neurodegenerative disease, hypertrophic cardiomyopathy, viral infections and metabolic diseases and disorders are also disclosed herein.Type: GrantFiled: October 6, 1998Date of Patent: November 5, 2002Assignee: CuraGen CorporationInventors: Krishnan Nandabalan, Vincent P. Schulz, Meija Yang
-
Patent number: 6379924Abstract: The use of a means to vary Ubc4p or Ubc5p activity in a fungal cell to control the copy number of a plasmid in the cell. The level of Ubc4p or Ubc5p activity may be reduced/abolished (for example by gene deletion, mutagenesis to provide a less active protein, production of antisense mRNA or production of competitive peptides) to raise the copy number and increase yield of a protein encoded by the plasmid.Type: GrantFiled: December 15, 1999Date of Patent: April 30, 2002Assignee: Delta Biotechnology Ltd.Inventor: Darrell Sleep
-
Patent number: 6290953Abstract: A method of modulating cellular proliferation by the application of a thymidine phosphorylase to an organism. In a further aspect of the subject method, the thymidine phosphorylase is a conjugate which includes a targeting portion adapted to target the conjugate to a specific cell type or anatomical location. The thymidine phosphorylase has a thymidine phosphorylase activity of at least about 5%, preferably at least about 50% and, most preferably, at least about 90%, of the native E. coli enzyme.Type: GrantFiled: January 11, 1996Date of Patent: September 18, 2001Assignee: Delta Biotechnology Ltd.Inventors: David J. Ballance, Michael G. Courtney, Christopher J. A. Finnis, Darrell Sleep
-
Patent number: 6150133Abstract: A process of culturing a microorganism in a culture medium in which process the addition of feed medium is controlled by using the production of a by-product as a measure of the culture conditions, characterized in that the by-product is an electrically charged metabolite produced by the microorganism, and in that the production of the metabolite is monitored by measuring the conductance of the culture medium. The metabolite may be acetate and the microorganism may be yeast which is genetically engineered to produce a desired polypeptide.Type: GrantFiled: September 11, 1998Date of Patent: November 21, 2000Assignee: Delta Biotechnology LimitedInventors: David John Mead, Hendrik Van Urk
-
Patent number: 6034221Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, fragments of albumin, polymers or aggregates of albumin, and viruses, and which is relatively non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through two chromatography purifications, ultrafiltering the product, passing through two further chromatography steps and again ultrafiltering the product.Type: GrantFiled: November 14, 1997Date of Patent: March 7, 2000Assignee: Delta Biotechnology LimitedInventors: Stephen Berezenko, John R. Woodrow, Richard A. Johnson, Patricia C. Wood, Steven J. Burton, Alan V. Quirk, David St. J. Coghlan, Mark J. Wilson
-
Patent number: 5965386Abstract: Albumin, for example human albumin, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45 kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and K414Q.Type: GrantFiled: November 11, 1996Date of Patent: October 12, 1999Assignee: Delta Biotechnology LimitedInventors: Sean Martin Kerry-Williams, Sarah Catherine Gilbert
-
Patent number: 5905143Abstract: When proteins are purified using a protein-binding dye immobilized on a chromatographic matrix, the dye or a portion/derivative may leak into the eluant. An ion-exchange resin (e.g. Dowex-1) and a disrupting material (e.g. salt and a fatty acid such as sodium octanoate) are used to separate the dye from the protein to overcome the protein of the leaking dye.Type: GrantFiled: February 28, 1997Date of Patent: May 18, 1999Assignee: Delta Biotechnology LimitedInventors: Richard A. Johnson, Alan V. Quirk, John R. Woodrow